TITLE

Initial combination anti-viral therapy with lamivudine and adefovir dipivoxil decreases short-term fatality rate of hepatitis-B-virus-related acute-on-chronic liver failure

AUTHOR(S)
Jiahong Yang; Gao Chen; Xuebing Chen; Hao Zhang; Di Jiang; Guang Yang
PUB. DATE
July 2015
SOURCE
Virology Journal;Jul2015, Vol. 12 Issue 1, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Acute-on-chronic liver failure (ACLF) is a common serious hepatitis B virus (HBV)-related disease and has a poor prognosis. Until recently, initial combination antiviral treatment in ACLF patients was rarely reported. This study evaluated the effect of initial combination treatment with lamivudine and adefovir dipivoxil on the prognosis of HBV-related ACLF. Methods: In this retrospective study, 131 eligible ACLF patients, including 61 treated with 100 mg lamivudine and 10 mg adefovir dipivoxil daily and 70 not treated with any nucleoside analogs (NAs), were selected and assigned into the NA and non-NA groups. All the patients received standard medicinal therapy. At weeks 0-4 and 12, serum markers for hepatic and renal functions were measured in all patients and accumulated fatality rates were calculated. Statistical analyses, including Student's t test, X2 test and unconditional logistic regression analysis, were performed using SPSS version 17.0 software. Results: Clinical data indicated that improvement of hepatic function was better in the NA than in the non-NA group. The accumulated fatality rate in the NA group was lower than in the non-NA group at weeks 2-4 and 12, and these differences were significant. Univariate analysis showed that age, prothrombin activity, model of end-stage liver disease (MELD) score, and treatment without NAs were risk factors for short-term survival of ACLF. Further research by unconditional logistic regression analysis identified that older age, high MELD score and treatment without NAs were independent risk factors for short-term survival of ACLF. Conclusions: Initial combination antiviral treatment is effective in decreasing short-term fatality of HBV-related ACLF.
ACCESSION #
108647361

 

Related Articles

  • Antiviral therapy for acute-on-chronic liver failure in chronic hepatitis B: is it too late? Henry Chan; Chan, Henry Lik-Yuen // Digestive Diseases & Sciences;Aug2010, Vol. 55 Issue 8, p2126 

    The author reflects on the significance of antiviral therapy to treat acute liver failure in chronic hepatitis B patients in Chengdu, China. It says that entecavir and tenofovir are recommended in U.S. and Europe in place for lamivudine due to their low risk of drug resistance. The author argues...

  • First-line tenofovir best for chronic hepatitis B in Canada.  // PharmacoEconomics & Outcomes News;12/10/2011, Issue 643, p3 

    The article reports that the first-line therapy using tenofovir disoproxil fumarate has been proven as the most cost-effective Nucleoside Reverse Transcriptase Inhibitor (NRTI) for treating patients with chronic hepatitis B in Canada.

  • CONTROLLED AND SUSTAINED RELEASE APPROACHES IN DEVELOPING SUITABLE DOSAGE FORMS FOR THE ANTIRETROVIRAL DRUG LAMIVUDINE. Vamshi Alla, Krishna; Praveen Kumar, Gannu; Cheruku, Vishvasa; Jannu, Anand; Kumari Bairi, Chaitanya // International Journal of Pharmaceutical Sciences Review & Resear;May/Jun2011, Vol. 8 Issue 1, p21 

    Lamivudine is a Nucleoside Reverse Transcriptase Inhibitor (NRTI), licensed for the treatment of HIV, and chronic Hepatitis B. The pharmacokinetic data of Lamivudine shows that, frequent administration for a prolonged period of time (lifelong in AIDS and for one year in hepatitis patients) is...

  • Lamivudine.  // AHFS Consumer Medication Information;Oct2019, p1 

    Lamivudine (Epivir) is used in combination with other medications to treat human immunodeficiency virus (HIV) infection in patients with acquired immunodeficiency syndrome (AIDS). Lamivudine is not a cure and may not decrease the number of HIV-related illnesses. Lamivudine does not prevent the...

  • Severe skin rash with lamivudine in HIV infected patients:Some unusual case reports. Modak, Dolanchampa; Guha, Subhasish Kamal // Indian Journal of Pharmacology;May/Jun2013, Vol. 45 Issue 3, p298 

    Lamivudine (3TC) is a nucleoside reverse transcriptase inhibitor (NRTI) licensed for as a first line drug in Human immunodeficiency virus (HIV) infection and also in the treatment of hepatitis B. It is relatively nontoxic in nature and potentiates the antiviral effects of other NRTIs like...

  • Quasispecies and Pre-Existing Drug-Resistant Mutations of Hepatitis B Virus in Patients with Chronic Hepatitis B. Do Young Kim; Hye Young Chang; Sun Min Lim; Seung Up Kim; Jun Yong Park; Ja Kyung Kim; Kwan Sik Lee; Kwang-Hyub Han; Chae Yoon Chon; Sang Hoon Ahn // Gut & Liver;May2013, Vol. 7 Issue 3, p329 

    Background/Aims: To investigate pre-existing hepatitis B virus (HBV) quasispecies and the genotypic evolution of several variants. Methods: From six patients with lamivudine (LAM) failure, serum samples at pretreatment, 6 months of LAM therapy, and virologic breakthrough were obtained. One...

  • Efficacy of Entecavir and Adefovir Combination Therapy for Patients with Lamivudine- and Entecavir-Resistant Chronic Hepatitis B. Jeon, Jung; Shin, Hyun; Lee, Joung; Joo, Kwang; Cha, Jae; Park, Jae; Lim, Jun; Lim, Kyuseong; Kim, Sunyong // Digestive Diseases & Sciences;May2012, Vol. 57 Issue 5, p1358 

    Background: The optimal treatment of patients with chronic hepatitis B (CHB) who develop resistance to both lamivudine (LMV) and entecavir (ETV) after sequential monotherapy of LMV and ETV remains little known. Methods: We evaluated the efficacy of entecavir (ETV) plus adefovir dipivoxil (ADV)...

  • The Efficacy of Adefovir Plus Entecavir Combination Therapy in Patients with Chronic Hepatitis B Refractory to Both Lamivudine and Adefovir. Cho, Yuri; Lee, Dong; Chung, Kwang; Jin, Eunhyo; Lee, Jeong-Hoon; Cho, Eun; Yu, Su; Kim, Jin; Jeong, Sook; Yoon, Jung-Hwan; Lee, Hyo-Suk; Kim, Chung; Kim, Yoon // Digestive Diseases & Sciences;May2013, Vol. 58 Issue 5, p1363 

    Background: The efficacy of adefovir (ADV) plus entecavir (ETV) combination in patients with chronic hepatitis B (CHB) who developed multidrug refractoriness had not been fully evaluated. We aimed to evaluate the efficacy of ADV plus ETV as compared to that of lamivudine (LAM) plus ADV in the...

  • Long-term efficacy and emergence of multidrug resistance in patients with lamivudine-refractory chronic hepatitis B treated by combination therapy with adefovir plus lamivudine. Suzuki, Fumitaka; Hosaka, Tetsuya; Suzuki, Yoshiyuki; Akuta, Norio; Sezaki, Hitomi; Hara, Tasuku; Kawamura, Yusuke; Kobayashi, Masahiro; Saitoh, Satoshi; Arase, Yasuji; Ikeda, Kenji; Kobayashi, Mariko; Watahiki, Sachiyo; Mineta, Rie; Kumada, Hiromitsu // Journal of Gastroenterology;Jun2014, Vol. 49 Issue 6, p1094 

    Background: Few studies have investigated the emergence of multidrug resistance to adefovir dipivoxil (ADV) plus lamivudine (LAM) combination therapy for patients with LAM-refractory chronic hepatitis B (CHB). In this retrospective study, we investigated the long-term clinical course of these...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics